Why the study?
Is there a role for vernakalant in the conversion of recent onset atrial fibrillation as the first approach to a rhythm-control strategy?
Is there a role for vernakalant in the conversion of recent onset atrial fibrillation as the first approach to a rhythm-control strategy?
Vernakalant is a relatively atrial-selective drug that inhibits atrial-selective K(+) currents, presenting an attractive alternative for pharmacological cardioversion of recent onset atrial fibrillation.
Supports vernakalant evaluation for recent-onset AF cardioversion; leaves open its role as initial rhythm-control strategy.
Conversion of recent onset atrial fibrillation (AF) to sinus rhythm with antiarrhythmic drugs reduces the risk of hemodynamic instability, hospitalizations, and atrial remodeling seen with persistent AF. This is the main reason for pharmacological or electrical cardioversion to be considered first line of treatment for recent onset AF. Is there a role for new antiarrhythmic drugs in the conversion of AF as the first approach to a rhythm-control strategy? Vernakalant is a novel and relativity atrial selective drug which inhibits atrial-selective K(+) currents, with only a small inhibitory effect on the rapidly activating delayed rectifier K(+) current (IKr) in the ventricle. In this brief Review, we tell the journey of vernakalant to become an attractive alternative to achieve pharmacological cardioversion of AF.
No takes yet. Share an insight, caveat, or question.
Conde et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: